Shares of Neurochem jumped this morning when the company announced plans to update its data on its Alzheimer's therapy Alzhemed. Neurochem's stock took off on a roller coaster ride last April as investors fretted over fears that the drug data was not good enough to satisfy regulators. The update is expected from its lead investigator at a conference later today, but the company has cautioned that no conclusions can yet be reached on the therapy.
- see the release
- read the AP report on the review